Core Viewpoint - Kangfu Bio-B (06922) has successfully completed the subscription agreement A, issuing a total of 5.595 million shares at a subscription price of HKD 5.36 per share, which represents approximately 3.90% of the H-shares issued prior to the completion of the agreement and about 2.34% of the total issued shares [1] Group 1 - The total amount raised from subscription agreement A is approximately HKD 29.99 million, with a net amount of about HKD 29.73 million after expenses [1] - The net subscription price per share, after deducting all related expenses, is approximately HKD 5.31 [1] - The proceeds from the subscription are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, as well as potential overseas business expansion for these products [1] Group 2 - Subscription agreement B has been terminated, releasing both parties from their obligations under the agreement without any claims against each other [1] - Following the termination of subscription agreement B, the issuance of the 5.595 million shares under subscription agreement A will result in approximately 3.75% of the H-shares issued after the share allocation and about 2.29% of the total issued shares [1]

Core Viewpoint - 康沣生物-B has successfully completed the subscription agreement A, issuing 5.595 million shares at a price of HKD 5.36 per share, which represents approximately 3.90% of the H-shares issued prior to the completion of the agreement and about 2.34% of the total existing shares [1] Group 1 - The total amount raised from the subscription agreement A is approximately HKD 29.99 million, with a net amount of about HKD 29.73 million after expenses [1] - The net subscription price per share, after deducting all related expenses, is approximately HKD 5.31 [1] - The proceeds from the subscription are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, as well as potential overseas business expansion for these products [1] Group 2 - The subscription agreement B has been terminated, releasing both parties from their obligations under that agreement without any claims against each other [1]

Core Viewpoint - 康沣生物-B (06922) has entered into a subscription agreement to issue a total of 7.46 million H shares at a subscription price of HKD 5.36 per share, representing a discount of approximately 17.79% compared to the closing price of HKD 6.52 on the Hong Kong Stock Exchange on the same day [1] Group 1: Subscription Details - The subscription agreement is with LP Investment Holdings Group and Mr. Li Jun [1] - The net proceeds from the subscription are approximately HKD 39.73 million [1] Group 2: Use of Proceeds - 80% of the proceeds will be allocated for research, production, and commercialization of minimally invasive interventional products related to vascular intervention, respiratory intervention, and tumor intervention [1] - 20% of the proceeds will be used for general working capital of the group [1]